Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVAJAK: Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myelo-proliferative neoplasms AVAJAK: Apixaban/rivaroxaban Versus Aspirine en prévention primaire des complications thromboemboliques des néoplasies myéloprolifératives mutées pour JAK2V617F

Next Previous
Trial Profile

AVAJAK: Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myelo-proliferative neoplasms AVAJAK: Apixaban/rivaroxaban Versus Aspirine en prévention primaire des complications thromboemboliques des néoplasies myéloprolifératives mutées pour JAK2V617F

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary) ; Rivaroxaban (Primary)
  • Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
  • Focus Therapeutic Use
  • Acronyms AVAJAK

Most Recent Events

  • 18 Jun 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top